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Indisulam (E7070) is an anticancer agent that is currently being evaluated in phase II clinical studies. A significant reduction in
glutathione synthetase and glutathione reductase transcripts by indisulam provided a molecular basis for its combination with
platinum agents. Indisulam demonstrated high anti-tumour activity in various preclinical cancer models. The objectives of this study
were (1) to determine the recommended dose of indisulam in combination with carboplatin in patients with solid tumours and (2) to
evaluate the pharmacokinetics of the combination. Patients with solid tumours were treated with indisulam in combination with
carboplatin. Indisulam (350, 500, or 600mgm
 2) was given as a 1-hour intravenous infusion on day 1 and carboplatin (5 or
6mgminml
 1) as an intravenous infusion over 30min on day 2 of a three-weekly cycle. Sixteen patients received study treatment
and were eligible. Thrombocytopenia was the major dose limiting toxicity followed by neutropenia. Both drugs contributed to the
myelosuppressive effect of the combination. Indisulam 500mgm
 2 in combination with carboplatin 6mgminml
 1 was identified not
to cause dose limiting toxicity, but a delay of re-treatment by 1 week was required regularly to allow recovery from
myelosuppression. The recommended dose and schedule for an envisaged phase II study in patients with non-small cell lung cancer is
indisulam 500mgm
 2 in combination with carboplatin 6mgminml
 1 repeated four-weekly. Patients who do not experience severe
thrombocytopenia at cycle 1 will be permitted to receive an escalated dose of indisulam of 600mgm
 2 from cycle 2 onwards.
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Indisulam (E7070) is a chloro-indolyl sulphonamide anticancer
agent that induces dose- and time-dependent G1 cell-cycle arrest
in addition to delay in G1/S transition and S-phase progression
(Fukuoka et al, 2001). Significant downregulation of particular sets
and subsets of genes involved in cell-cycle control and energy
metabolism was observed. Inhibition of carbonic anhydrase
isoform IX (CAIX), which was initially supposed to be the main
mechanism of action does not appear to be able to explain the
whole aspects of indisulam anti-tumour activity (Owa et al, 2004).
Very recently, indisulam was found to promote the production of
reactive oxygen species before cellular apoptosis. Several de-
hydrogenase enzymes have been identified so far as indisulam
binding proteins, suggesting that the cellular redox control system
connected with mitochondrial functions might be a potential
primary target of indisulam (Oda et al, 2003).
A single agent phase II study revealed evidence of only weak
activity and an acceptable toxicity profile in patients with non-
small cell lung cancer (NSCLC), who had received prior treatment
with platinum-based chemotherapy (Talbot et al, 2002).
Preclinical studies indicated that the combination of indisulam
with platinum was synergistic in both cell line isobologram
analysis and in NSCLC xenograft models, possibly by reducing
intracellular glutathione (Ozawa et al, 2004). Sequencing carbo-
platin 1 day after the application of indisulam is based on
experiments with human tumour xenografts in nude mice in which
a significant downregulation of glutathione synthetase mRNA was
detected by quantitative real-time polymerase chain reaction
(RT-PCR) 24h after administration of indisulam. As this enzyme
is critical to maintain intracellular levels of glutathione that
inactivates platinum species, this sequence guarantees non-
compromised anti-tumour activity of carboplatin given on day 2
after indisulam (Owa T, Eisai Co Ltd, Japan; personal commu-
nication).
The currently presented dose escalation study was performed to
identify a safe dose of indisulam in combination with carboplatin
that can be tested in patients with NSCLC or other platinum-
sensitive malignancies. For more than a decade, platinum-based
chemotherapy represents the standard of care for NSCLC (Bunn
et al, 1994). In a recently published prospectively randomised
phase III study which compared four different platinum containing
doublets, no significant difference with regard to response and
survival was detected between three cisplatin- and one carboplatin-
containing regimen (Schiller et al, 2002). The carboplatin-containing
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streatment arm was associated with even less toxicity overall,
particularly with respect to febrile neutropenia and nausea. In a
recent survey, a carboplatin-containing combination was found to
be the most widely favoured option for first-line chemotherapy in
all stages of NSCLC among US medical oncologists (Choy et al,
2000). This relates to ease of administration on an out-patient
basis, manageable toxicity profiles compared with other platinum-
containing regimens and promising phase II trial results (Langer
et al, 1995; Muggia et al, 1995; Belani et al, 1996; Johnson et al,
1996).
The objectives of this study were (1) to determine the
recommended dose of indisulam in combination with carboplatin
in patients with solid tumours and (2) to evaluate the pharmaco-
kinetics of the combination.
PATIENTS AND METHODS
Eligibility
Patients, X18 years old, with a histologically/cytologically
confirmed solid tumour refractory to standard therapy or for
whom no established therapy exists were eligible. Their Karnofsky
performance status must have been X70%; they had to present
with adequate haematological, renal and hepatic function as
defined by absolute neutrophil count of X1.5 10
9l
 1; platelet
count of X100 10
9l
 1; haemoglobin level of X10gdl
 1; serum
bilirubin p1.5 times the upper limit of normal, alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
p2.5 times the upper limit of normal (p5 times the upper limit of
normal in the presence of hepatic metastases); and serum
creatinine p1.5 times the upper limit of normal or a creatinine
clearance X60mlmin
 1 (by Cockcroft-Gault formula).
Each of the following conditions represented an exclusion
criterion: more than two previous lines of chemotherapy;
incomplete recovery from surgery or radiation therapy; previous
chemotherapy within 4 weeks of study entry; uncontrolled
infections; significant cardiac impairment; and history of sensi-
tivity to sulphonamides or platinum agents.
Written informed consent fulfilling the requirements of the
ethics committee was required to be obtained from all patients
before entry into the study.
Treatment plan and study design
Indisulam dosing was based on body surface area and carboplatin
doses were calculated with the Calvert formula to produce an area
under the concentration–time curve (AUC) of 5 or 6mgminml
 1
(Calvert et al, 1989; van Kesteren et al, 2002). The starting dose of
the combination was indisulam 350mgm
 2 administered as a 1-h
intravenous infusion on day 1 and carboplatin 6mgminml
 1 as a
30-min infusion on day 2, repeated every 3 weeks. The dose
escalation scheme is summarised in Table 1. The dose of indisulam
was to be escalated in subsequent cohorts consisting of three
patients to 500, 600 and 700mgm
 2 according to the toxicity
observed at prior dose levels. If one of the first three patients
experienced dose-limiting toxicity (DLT) during cycle 1, the
number of patients treated at this dose level was expanded to six.
Provided that none of the additional three patients experienced a
DLT during cycle 1, dose escalation was continued. When a dose of
indisulam was reached at which X33% of the patients in a cohort
of six experienced DLT during their first cycle of the combination,
the dose of carboplatin was reduced from 6 to 5mgminml
 1. If the
maximum tolerated dose (MTD) of indisulam was well tolerated in
combination with carboplatin 5mgminml
 1, the indisulam dose
was finally escalated to the next dose level.
Patient evaluation and follow-up
Patients attended the clinic for a screening visit up to 14 days
before treatment start to assess eligibility. Physical examination
was performed as well as Karnofsky performance status was
assessed at screening and vital signs as well as laboratory
assessment (urinalysis, haematology, clinical chemistry) were
carried out weekly till the final visit 30 days after the last intake
of study drug. Patients were followed up for survival.
Tumour assessments according to RECIST criteria were carried
out at screening and then every 6 weeks. ECGs were taken at
screening and before and after study drug administration at day 1
only. Adverse events and concomitant medications were recorded
on an ongoing basis from the date of consent until the final visit.
Dose limiting toxicities were assessed in the first cycle of
treatment and were defined according to version 2.0 of the NCI
common toxicity criteria (CTC): (i) Xgrade 3 non-haematological
toxicity directly related to study treatment (other than untreated
nausea and vomiting), (ii) grade 4 thrombocytopenia, (iii) grade 4
neutropenia for X7 days and (iv) Xgrade 3 febrile neutropenia.
Dose reductions for unacceptable toxicity up to a maximum of
two per patient were permitted. Once, the dose had been reduced it
was not increased at a later date. A delay of up to 2 weeks was
permitted in between cycles.
Pharmacokinetic study
Full pharmacokinetic sampling of indisulam and carboplatin were
performed during the first cycle of treatment. Blood samples (4ml)
for indisulam analysis were obtained at 15 time points for up to 8
days after the first administration: pre-infusion, 30min after the
start of infusion, at the end of the infusion, at 10 and 30min and
at 1, 2, 4, 6, 8, 24, 48, 72, 96 and 168h after the end of the infusion.
In addition, indisulam samples were taken before infusion and at
the end of infusion during cycle 2. Immediately after collection,
the samples were centrifuged at room temperature for 10min at
1500g. Plasma was collected and immediately stored at  201C
until analysis. The concentrations of indisulam in plasma were
measured using high-performance liquid chromatography coupled
to an electrospray ionization tandem mass spectrometer (LC/ESI-
MS/MS) as described previously (Beumer et al, 2004).
Blood samples (5ml) for carboplatin analysis were obtained at
eight time points on day 1: before administration, at the end of
infusion and at 1, 2, 4, 6, 8 and 23h after the end of infusion.
Immediately after collection, the samples were centrifuged at 41C
for 5min at 1500g. Immediately after centrifugation for plasma
separation, aliquots of the collected plasma were transferred to
Amicon ultrafiltration devices with an YMT-14 membrane (30kDa
MW cutoff; Millipore Corporation, Bedford, MA, USA). Ultrafil-
trate was prepared by centrifuging this device at 1500g for 15min
at room temperature. The plasma ultrafiltrates were stored frozen
at  201C until analysis of free platinum; the remaining plasma was
stored frozen at  201C until analysis of total platinum. Plasma
concentrations were measured by graphite-furnace atomic-absorp-
tion spectrometry (van Warmerdam et al, 1995).
Table 1 Summary of planned dose escalation scheme
Dose level
Indisulam (mgm
 2)
day 1
Carboplatin (mgminml
 1)
day 2
One 350 6
Two 500 6
Three 600 6
Four 700 6
X Maximum tolerated dose 5
X+1 Maximum tolerated dose + one 5
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sPopulation pharmacokinetic analysis
The pharmacokinetic profile of indisulam monotherapy was
described previously by a population pharmacokinetic model
using nonlinear mixed effects modelling (Zandvliet et al,
2006). The model consisted of multiple compartments corres-
ponding to plasma, erythrocytes, interstitial fluid and tissue.
Indisulam was eliminated via two pathways: a linear and
a saturable pathway. The pharmacokinetic parameters describing
the model for indisulam monotherapy were applied to calculate
model predicted indisulam concentrations, which were compared
to the observed plasma concentration of indisulam. If the
model adequately predicted the observed concentrations, it could
be concluded that the pharmacokinetic profile of indisulam
was not highly influenced by combination therapy with carbo-
platin. The population pharmacokinetic analyses were performed
using NONMEM software (version V, level 1.1) (GloboMax LLC,
Hanover, MD, USA) after logarithmic transformation of the data
(Beal et al, 1988).
The pharmacokinetic results of ultrafiltrable carboplatin
were also evaluated by compartmental analysis using NONMEM
software. The data were fitted to a linear two-compartment
model (Huitema et al, 2000; Shen et al, 2002; Ekhart et al,
2006). Pharmacokinetic parameters were compared to previously
published reports (Huitema et al, 2000; Shen et al, 2002;
Ekhart et al, 2006). Differences may indicate a pharmaco-
kinetic interaction between carboplatin and indisulam. Further-
more, the observed carboplatin clearance of the studied patients,
as determined by the population pharmacokinetic analysis,
was compared to the predicted carboplatin clearance, as
calculated using the Calvert formula (Eq. 1) (Calvert et al,
1989). Calvert et al (1989) demonstrated that the total plasma
clearance of carboplatin was linearly related to the glomerular
filtration rate (GFR) and that the non-renal clearance was
25mlmin
 1.
CLcarboplatin ¼ GFR þ 25 ð1Þ
The estimated creatinine clearance (CLcr) was considered as a
measure of GFR and was calculated from measured serum
creatinine (CR,mmoll
 1), age (years), gender (0¼male,
1¼female) and weight (kg) using the Cockcroft and Gault’s
(1976) formula:
CLcr ¼
ð140   ageÞðweightÞð1   0:15 genderÞ
72ðCRÞ0:0113
ð2Þ
Serum creatinine levels were measured by enzymatic methods. If
the observed carboplatin clearance corresponded well to the
predictions from the Calvert formula, it could be concluded that
the clearance of carboplatin was not affected by indisulam.
Pharmacokinetic-pharmacodynamic analysis
Relationships between drug exposure and platelet counts were
explored to find potential relationships between pharmacokinetics
and haematological toxicity. The area under the plasma concen-
tration vs time-curve (AUC) of indisulam and carboplatin
ultrafiltrate were used as measures of drug exposure in this
analysis. The relationship between the nadir platelet count and the
exposure to indisulam (AUCind) and carboplatin (AUCcarb) at cycle
1 was described by a modified Hill equation:
nadirplateletcount
baselineplateletcount
¼
1  
AUC
g1
ind
ðAUC
g1
ind þ AUC50
g1
indÞ
 !
1  
AUC
g2
carb
ðAUC
g2
carb þ AUC50
g2
carbÞ
 ! ð3Þ
RESULTS
Dose escalation and safety assessment
Seventeen patients registered for the study; 16 patients received
treatment with indisulam and carboplatin. Characteristics of
eligible patients are listed in Table 2.
Patients were treated at four different dose levels (Table 3). Four
patients were treated with 350mgm
 2 indisulam and
6mgminml
 1 carboplatin. One patient died from progressive
disease before completing 1 cycle of study treatment and was
therefore replaced in the cohort. Three patients were treated at the
second dose level. At the initial two dose levels, no DLTs were
Table 2 Patient characteristics
Gender
Male 5 (31%)
Female 11 (69%)
Age (years)
Median 63
Range 19–81
Height (cm)
Median 164
Range 153–185
Race
Caucasian 16 (100%)
Time since diagnosis (months)
Median 30
Range 2–335
Tumour type
Sarcoma 3
Renal cell 2
Lung 2
Colorectal 2
Ovarian 2
Pancreas 2
Adenocarcinoma 1
Melanoma 1
Gastric 1
Previous therapy
Surgery 16 (100%)
Radiotherapy 5 (31%)
Chemotherapy, 1 course 5 (31%)
Chemotherapy, 2 courses 4 (25%)
Chemotherapy, 3 courses 1 (6%)
Chemotherapy, 4 courses 2 (13%)
Experimental therapy 4 (25%)
Table 3 Number of patients, DLTs, dose reductions per dose level
Indisulam
(mgm
 2)
Carboplatin
(mgminml
 1)
Number of
patients treated DLTs
Patients with
dose reductions
at cycle 2
350 6 4
a 00
500 6 3 0 0
600 6 4 3 (75%) 2
600 5 5
b 2 (50%)
c 0
DLTs, dose limiting toxicities.
aOne patient was not assessable for DLT, because he
died due to progressive disease during cycle 1.
bOne patient was not assessable for
DLT, because she died due to progressive disease during cycle 1
cTwo DLTs out of
four assessable patients.
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sobserved and the combination was well tolerated at cycle 1.
However, all patients who received more than one treatment cycle
required a delay in the start of subsequent cycles to recover from
haematological toxicity. Four patients were treated at dose level 3.
At cycle 1, two patients had dose-limiting grade 4 thrombocyto-
penia and one patient had grade 3 thrombocytopenia with
haemorrhage (this was not defined as a DLT, but was considered
as one by the investigator as it yielded consecutive partial liver
resection owing to the intra-hepatic bleeding). A fourth patient in
this cohort experienced CTC grade 4 neutropenia at cycle 3. The
MTD of indisulam when administered in combination with
carboplatin was consequently defined as 600mgm
 2. Consecu-
tively, five patients were treated with 600mgm
 2 indisulam and
5mgminml
 1 carboplatin. Two patients experienced DLTs at
cycle 1 at this dose.
Overall, indisulam 600mgm
 2 in combination with carboplatin
was too toxic. Nonetheless, a dose of 500mgm
 2 indisulam and
carboplatin 6mgminml
 1 was considered to be safe at cycle 1.
A total of 53 cycles of the combination were delivered, with a
median of 2 cycles and a range of 1–7 cycles. Of 37 doses that were
administered after the first treatment cycle, 30 (81%) were delayed
by 1 or 2 weeks owing to unresolved thrombocytopenia and/or
neutropenia.
Sixteen patients were evaluated for toxicity. Table 4a represents
a summary of treatment-related adverse events. Nearly all severe
adverse events were haematological toxicities (thrombocytopenia,
neutropenia and anaemia) occurring by day 15 of each cycle, and
resolving after at least 7 days. Table 4b shows the number of
patients with haematological toxicity CTC grade 3 or 4 at cycle 1
and post cycle 1. Thrombocytopenia was the major DLT at cycle 1.
Furthermore, all patients who received more than one treatment
cycle experienced thrombocytopenia as a result of the combination
treatment with indisulam and carboplatin. Non-haematological
side effects were minor and can be neglected.
Severe adverse events related to study treatment reported during
the study were: grade 4 thrombocytopenia (2), grade 3 thrombo-
Table 4a Treatment-related adverse events observed during the study by worst grade according to the NCI-common toxicity criteria (CTC)
Dose level
a 350/6 500/6 600/6 600/5 All
Number of evaluable patients 4 3 4 5 16
CTC grade 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
Haematological adverse events
Thrombocytopenia 0 3 0 2 1 2 0 4 1 (6%) 11 (69%)
Neutropenia 1 2 1 1 0 3 0 4 2 (12.5%) 10 (62.5%)
Anaemia 2 1 1 1 0 3 1 2 4 (25%) 7 (44%)
Non-haematological adverse events
Fatigue 3 0 3 0 3 0 4 0 13 (81%) 0 (0%)
Nausea 2 0 2 0 2 0 2 0 8 (50%) 0 (0%)
Vomiting 3 0 0 0 2 0 1 0 6 (37.5%) 0 (0%)
Constipation 2 0 1 0 3 0 0 0 6 (37.5%) 0 (0%)
Dysgeusia 0 0 1 0 1 0 2 0 4 (25%) 0 (0%)
Anorexia 1 0 1 0 1 0 1 0 4 (25%) 0 (0%)
Abdominal pain 2 0 0 0 2 0 0 0 4 (25%) 0 (0%)
Dry mouth 1 0 0 0 1 0 1 0 3 (19%) 0 (0%)
Flatulence 1 0 1 0 1 0 0 0 3 (19%) 0 (0%)
Diarrhoea 1 0 0 0 1 0 0 0 2 (12.5%) 0 (0%)
Headache 1 0 0 0 1 0 0 0 2 (12.5%) 0 (0%)
Dyspepsia 1 0 1 0 0 0 0 0 2 (12.5%) 0 (0%)
Peripheral oedema 0 0 1 0 0 0 1 0 2 (12.5%) 0 (0%)
Dry skin 1 0 1 0 0 0 0 0 2 (12.5%) 0 (0%)
aIndisulam (mgm
 2)/carboplatin (mgminml
 1).
Table 4b Number of patients with any treatment-related haematological toxicity grade 3 or 4 according to the NCI-common toxicity criteria (CTC) at
cycle 1 and post cycle 1
Dose level
a 350/6 500/6 600/6 600/5 All
Number of evaluable patients 4 3 4 5 16
CTC grade 34343434 3 4
Cycle 1
Platelets 0 0 1012315 (31%) 3 (19%)
Neutrophils 0 0 0011011 ( 6 % ) 2 (13%)
Leucocytes 0 0 0010112 (13%) 1 (6%)
Lymphocytes 0 0 0000101 ( 6 % ) 0 ( 0 % )
Haemoglobin 0 0 0001202 (13%) 1 (6%)
Post cycle 1
Platelets 3 0 211241 1 0 (63%) 4 (25%)
Neutrophils 2 0 2132249 (56%) 7 (44%)
Leucocytes 2 0 1010428 (50%) 2 (13%)
Lymphocytes 1 0 0000304 (25%) 0 (0%)
Haemoglobin 2 0 1020207 (44%) 0 (0%)
aIndisulam (mgm
 2)/carboplatin (mgminml
 1).
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anaemia (1) and grade 2 supra-ventricular tachycardia (1).
Three patients died on study (within 30 days of last study
treatment) due to progressive disease. Six patients withdrew due
to adverse events, four due to progressive disease according to
RECIST criteria, three due to clinical progressive disease, one due
to abnormal laboratory values (neutropenia grade 3) and one
withdrew consent.
Response
Ten patients completed at least two cycles of study treatment and
were evaluable for response. Eight patients showed stable disease
and two patients had progressive disease.
Population pharmacokinetic analysis
Sixteen patients were evaluable for pharmacokinetics. Time
profiles of indisulam plasma concentrations were adequately
described by the population pharmacokinetic model. Observed
indisulam plasma concentrations corresponded well to the model-
based predictions (Figure 1). The median exposures to indisulam
expressed as the AUC were 47, 94 and 116mgminml
 1 for dose
levels 350, 500 and 600mgm
 2 and AUCs ranged from 25 to
198mgminml
 1.
The two-compartmental model produced a good fit to the
ultrafiltrable carboplatin concentrations. Estimated pharmaco-
kinetic parameters are listed in Table 5. Carboplatin clearance
was lower than in previous studies. Conversely, the intercompart-
mental clearance was relatively high. Other parameters corre-
sponded well to published values. Figure 2 shows that the
carboplatin clearance was overpredicted by the Calvert formula
for all patients. This resulted in a carboplatin exposure that was
higher than the target exposure. The median exposure was
6.1mgminml
 1 for target 5mgminml
 1 and 6.7mgminml
 1
for target 6mgminml
 1. Carboplatin AUC ranged from 5 to
10mgminml
 1.
Pharmacokinetic-pharmacodynamic analysis
The severity of thrombocytopenia was expressed as the nadir
platelet count and was related to the exposure to indisulam and
carboplatin. Myelosuppression was assessed at the first treatment
cycle. Fourteen patients were evaluable for this PK-PD analysis.
Their nadir platelet count ranged from 4 10
9 to 154 10
9l
 1
corresponding to a range of 1.2–45% of the baseline platelet count.
The relative nadir platelet count, expressed as a percentage of the
baseline platelet count, decreased with both indisulam AUC
(P¼0.003) and carboplatin AUC (P¼0.004). The AUC of
indisulam resulting in a 50% decrease in platelet count (AUC50ind
in Eq. 3) was estimated at 28.5mgminml
 1 (relative standard
error (RSE) 21%). The thrombocytopenic effect of carboplatin was
half maximal at an AUC of 7.74mgminml
 1 (RSE 13%)
(AUC50carb in Eq. 3). The Hill factor g1 was not significantly
different from 1 (P¼0.57). The myelosuppressive effect of
carboplatin was best described by a sigmoidal Emax model and g
2
was estimated at 10.9 (RSE 70%). The relationship between the
relative nadir platelet count and the exposure to indisulam and
carboplatin is depicted in Figure 3A and B. The model predicted
nadir platelet counts were unbiased and corresponded reasonably
well to the observed values (Figure 3C). The modified Hill equation
adequately described the relative nadir platelet count after
treatment with indisulam in combination with carboplatin.
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Figure 1 Observed vs model predicted plasma concentrations of
indisulam. The scatter plot is symmetrically positioned around the line of
identity, which indicates that the currently observed profiles are well
described by the previously developed population pharmacokinetic model.
Table 5 Population pharmacokinetic parameter estimates of carboplatin ultrafiltrate
Pharmacokinetic parameter Previous reports
a Current estimate (%SE) IIV% (%SE)
Clearance CL (lh
 1) 6.06–8.33 4.87 (6) 12.4 (29)
Central volume of distribution V1 (l) 14.4–16.3 15.5 (20) 66.2 (147)
Intercompartmental clearance Q (lh
 1) 0.792–1.70 3.46 (18) 28.3 (39)
Peripheral volume of distribution V2 (l) 7.07–10.4 9.94 (11) 19.8 (41)
Correlation coefficientr CLBV1 0.67
Proportional residual error (%) 9.50 (11)
SE, standard error; IIV, interindividual variability.
aHuitema et al, (2000); Shen et al, (2002); Ekhart et al, (2006).
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Figure 2 Observed carboplatin clearance (CL) vs predicted carboplatin
clearance based on Cockcroft and Gault (1976) and Calvert et al (1989).
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sDISCUSSION
Both, the weak anti-tumour activity of indisulam as single agent at
a dosage of 700mgm
 2 as intravenous infusion over 1h every 3
weeks, demonstrated by tumour regressions of lesser degree than
required for an objective response in about third of the patients
treated and the low rate of toxicity with less than a quarter of all
patients experiencing grade 3 or 4 haematological toxicity, which
represented the main toxicity, did not only justify but merely
prompted us to combine indisulam with a substance with known
anti-tumour activity against NSCLC (Talbot et al, 2002). As a
consequence, carboplatin was selected (Bunn et al, 1994; Langer
et al, 1995; Muggia et al, 1995; Belani et al, 1996; Johnson et al,
1996; Choy et al, 2000; Schiller et al, 2002).
Haematological toxicity was dose limiting for indisulam in
combination with carboplatin. Minimal non-haematological toxi-
city was observed after treatment with the combination.
A dose of 500mgm
 2 indisulam and 6mgminml
 1 carboplatin
was well tolerated at cycle 1. However, dose delays were common
due to prolonged marrow recovery from the previous treatment.
Therefore, a 3-weekly treatment cycle was not sustainable. Thus,
for a future phase II study with indisulam and carboplatin in
chemotherapy naı ¨ve patients with NSCLC, a 4-weekly schedule was
proposed. In this phase II study, patients will be treated with the
safe dose of 500mgm
 2 indisulam with 6mgminml
 1 carboplatin
at cycle 1. Patients with minor thrombocytopenia (less than grade
3) at cycle 1 may receive an escalated dose of indisulam of
600mgm
 2 at cycle 2, because previous studies have demonstrated
a high correlation between the extent of prior chemotherapy and
the incidence of haematological toxicity.
Myelosuppression was previously identified as the DLT for
single agent therapy with both indisulam and carboplatin (Calvert
et al, 1982; Raymond et al, 2002). Thrombocytopenia was
identified as the major toxicity of the combination. The nadir
platelet count decreased with increasing exposure to both
indisulam and carboplatin. This phenomenon can be interpreted
as the result of the addition of a similar behaviour of the two
substances by increasing their dosages separately, but not
primarily as the result of its pharmacodynamic interaction. Single
agent high dose carboplatin, that is, 520–1000mgm
 2, covering
the exposure of an AUC ranging from 5 to 10mgminml
 1, which
was reached in our study, yielded severe and cumulative bone
marrow suppression in ovarian cancer patients (Wiltshaw et al,
1987). Both, leucopenia and thrombocytopenia reached their
nadirs at day 15; leucopenia o1000leucocytesml
 1 lasted 4 days
(range 1–11 days), thrombocytopenia o100000plateletsml
 1
lasted 12 days (range 4–40 days). Recommendations for target
AUC for obtaining an acceptable degree of myelosuppression
resulted in an AUC of 5–7mgminml
 1 for carboplatin single
agent therapy and in an AUC of 4–5mgminml
 1, when the drug
was to be used in combination with other myelosuppressive agents
(Calvert et al, 1989). In a phase II study in which carboplatin was
tested at an AUC of 7mgminml
 1 – corresponding well with the
median exposure of 6.7mgminml
 1 for target AUC 6mgminml
 1
in our study – every 4 weeks in advanced breast cancer patients,
leucopenia at the time of scheduled re-treatment was found to be
of grade 3 in 6% of the patients, of grade 2 in 15% and of grade 1 in
22%; the respective value for thrombocytopenia was grade 3 in 5%
of the patients (O’Brien et al, 1993). Martin et al (1992), who tested
a dosage of only 400mgm
 2, every 4 weeks, in metastatic breast
cancer patients, observed only infrequent and mild leucopenia and
thrombocytopenia on day 28. Overall, leucopenia of only WHO
grade 1–2 was found in 47% of the patients or 18% of the courses
and thrombocytopenia in 12% of the patients or 3% of the courses,
respectively. A scarce trial in which carboplatin was tested at a
3-weekly period, as foreseen in our study, but at a dosage of only
400mgm
 2 in metastatic breast cancer patients, yielded leuco-
penia grade 3–4 in two out of 20 (10%) patients and thrombo-
cytopenia grade 3 in one out of 20 (5%) patients as worst
haematological toxicities. But, due to permanent myelosuppres-
sion, five cycles of carboplatin could be administered to only three
patients (Kolaric ´ and Vukas, 1991). Overall, the prolonged
cytopenia concerning both platelets and neutrophils, which was
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Figure 3 The relative nadir platelet count vs exposure to indisulam (A)
and exposure to carboplatin (B). The solid lines represent the model
predicted nadir counts after median exposure to carboplatin
(6.7mgminml
 1) and varying exposure to indisulam (A) or after median
exposure to indisulam (94mgminml
 1) and varying exposure to
carboplatin (B). A plot of model predicted values vs the corresponding
observed values (C) is symmetrically distributed around the line of unity,
which demonstrates that the modified Hill equation resulted in unbiased
predictions of the nadir platelet count. AUC, area under the plasma
concentration vs time curve.
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single agent carboplatin.
Conversely, these toxicities are at least not caused by indisulam
single agent therapy. Thrombocytopenia usually occurred later
than leucopenia between days 9 and 14 and was of short duration
(median 3 days; range 1–6 days). Leucopenia typically occurred at
day 8 (range days 7–12) of the first cycle, and was associated with
neutropenia at day 10 (range days 6–11), lasted for a median
period of 8 days (range 7–9 days) and was fully reversible. Of the
21 cycles of indisulam given at the 700mgm
 2 dose level as 1h
infusion, every 3 weeks, to heavily pretreated patients, grade 3 or 4
neutropenia, thrombocytopenia or anaemia was reported in two
cycles (9.5%), three cycles (14%) and one cycle (4.7%), respectively
(Raymond et al, 2002).
The exposure to carboplatin was higher than anticipated in all
patients owing to overestimation of the carboplatin clearance by
application of the Calvert formula (with GFR estimated by CLcr
derived from Cockcroft-Gault). Consequently, higher doses than
required to reach the predefined AUC values were administered.
This has contributed to the high level of haematological toxicity
that was observed in this study. In addition to the relatively high
exposure to carboplatin, a pharmacodynamic interaction with
indisulam may have caused excessive haematological toxicity in
this study. Indisulam reduces the transcription of glutathione
transcriptase and glutathione reductase resulting in a reduction of
intracellular glutathione levels. This may not only enhance anti-
tumour activity of carboplatin, but it may also increase
haematological toxicity. This hypothesis is supported by the effect
of L-carnitine, which protects against carboplatin-induced myelo-
suppression by increasing the intracellular glutathione content
during treatment with carboplatin (Abd-Allah et al, 2005).
Obviously, it cannot be excluded, but is merely to be expected
that the synergism determined for the combination of the two
drugs in preclinical experiments is the reason for the observed
prolonged cytopenia of both platelets and neutrophils as observed
in our study.
The pharmacokinetic characteristics of indisulam were not
significantly affected by carboplatin, which was demonstrated by
the lack of bias in Figure 1. Carboplatin clearance was lower than
previously reported values and consistently lower than predicted
by the Calvert formula (Figure 2). It is unlikely that indisulam
affects renal elimination of carboplatin, because only seven out of
391 patients that had previously been treated with indisulam had
renal dysfunction. More probably, the low carboplatin clearance
was related to overestimation of the GFR by two mechanisms.
Serum creatinine is often assumed to be eliminated by passive
renal elimination only. However, active tubular secretion accounts
for about 20% of creatinine clearance. The tubular secretion may
be counterbalanced by overestimation of the serum creatinine level
as a result of the interference of non-creatinine chromogens with
the alkaline picrate method of Jaffe (Diskin, 2006). Conversely, in
our study, serum creatinine levels were measured by more accurate
enzymatic methods. The consequent lack of a compensation for
the tubular secretion of creatinine may have caused an over-
estimation of the GFR and consequently of the carboplatin
clearance.
In conclusion, this study showed that the combination of
indisulam with carboplatin was safe and a MTD for the phase II
study was identified. The three-weekly treatment schedule was not
feasible owing to thrombocytopenia and was therefore extended to
a four-weekly regimen.
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